ARMO Biosciences Has 'Potential Blockbuster' Cancer Drug In Pipeline, BMO Says
February 20, 2018 at 13:59 PM EST
Late-stage immuno-oncology company ARMO Biosciences Inc (NASDAQ: ARMO) recently went public last month, offering 7.53 million shares ...
